Caribou Biosciences Past Earnings Performance
Past criteria checks 0/6
Caribou Biosciences's earnings have been declining at an average annual rate of -29.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 32.7% per year.
Key information
-29.5%
Earnings growth rate
27.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 32.7% |
| Return on equity | -52.7% |
| Net Margin | -1,290.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 05
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Sep 30Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
Jul 26Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 13Caribou Biosciences: Selling Close To Cash Balance
Apr 26We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate
Oct 26Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
Oct 12Revenue & Expenses Breakdown
How Caribou Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11 | -148 | 42 | 0 |
| 30 Jun 24 | 33 | -123 | 46 | 0 |
| 31 Mar 24 | 33 | -115 | 44 | 0 |
| 31 Dec 23 | 34 | -102 | 38 | 0 |
| 30 Sep 23 | 35 | -95 | 37 | 0 |
| 30 Jun 23 | 14 | -111 | 37 | 0 |
| 31 Mar 23 | 15 | -108 | 37 | 0 |
| 31 Dec 22 | 14 | -99 | 38 | 0 |
| 30 Sep 22 | 13 | -91 | 37 | 0 |
| 30 Jun 22 | 13 | -85 | 34 | 0 |
| 31 Mar 22 | 11 | -73 | 29 | 0 |
| 31 Dec 21 | 10 | -67 | 24 | 0 |
| 30 Sep 21 | 8 | -63 | 21 | 0 |
| 30 Jun 21 | 5 | -50 | 17 | 0 |
| 31 Mar 21 | 12 | -38 | 15 | 0 |
| 31 Dec 20 | 12 | -34 | 14 | 0 |
| 31 Dec 19 | 6 | -23 | 16 | 0 |
Quality Earnings: CRBU is currently unprofitable.
Growing Profit Margin: CRBU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRBU is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.
Accelerating Growth: Unable to compare CRBU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CRBU has a negative Return on Equity (-52.67%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caribou Biosciences, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |